ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "risk factors"

  • Abstract Number: 1635 • ACR Convergence 2025

    Association Between Treatment Adherence and Frailty in Patients with Rheumatic Diseases

    Daniela L. Guillen-Tejada1, Aura Matilde Jiménez-Garduño1 and Montserrat Lamuño Encorrada2, 1Universidad de las Américas Puebla, Puebla, Mexico, 2Hospital Ángeles Puebla, Puebla, Mexico

    Background/Purpose: Management of rheumatic diseases relies on chronic treatment, often with a greater risk of nonadherence. Frailty is characterized by decreased physiological function that increases patients’…
  • Abstract Number: 2286 • ACR Convergence 2025

    Association of Semaglutide Prescription with Improved Joint Outcomes in Rheumatoid Arthritis Patients

    Faissal Stipho1, Yazin Hindosh2, Jonathan Sayegh2, Akram Hindosh2, Bassam Mitri2 and Issa Batarseh1, 1Department of Internal Medicine, Banner University Medical Center / University of Arizona, Tucson, Arizona, Tucson, AZ, 2University of Arizona College of Medicine Tucson, Tucson, AZ

    Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune disorder that results in immune dysfunction and swelling of major joints, leading to discomfort, pain, stiffness, and loss…
  • Abstract Number: 0133 • ACR Convergence 2025

    Differences in cardiovascular risk factor control between primary and systemic lupus erythematosus-related antiphospholipid syndrome in a multiethnic cohort of 1003 patients with antiphospholipid syndrome: the SUrvey of cardiovascular disease Risk Factors (SURF) in SLE and APS project

    Eleana Bolla1, Anne Grete Semb2, Michelle Petri3, Petros Sfikakis4, Bahar Artim Esen5, Gabriela Hernandez-Molina6, Eric Hachulla7, Haner Direskeneli8, George Karpouzas9, Marta Mosca10, Mohit Goyal11, Nathalie Costedoat-Chalumeau12, Angela Tincani13, Ayten Yazici14, Karoline Lerang15, Anne Troldborg16, Sofia Ajeganova17, Tatiana Popkova18, Elisabet Svenungsson19, Nikos Pantazis20 and Maria Tektonidou21, 1Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece, 2Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 3Johns Hopkins University School of Medicine, Timonium, MD, 4NKUA - SCHOOL OF MEDICINE, Athens, Greece, 5Istanbul University, Istanbul, Istanbul, Turkey, 6Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Federal District, Mexico, 7University of Lille, LILLE, France, 8Marmara University, ISTANBUL, Turkey, 9Harbor-UCLA Medical Center, Torrance, CA, 10University of Pisa, Pisa, Pisa, Italy, 11CARE Pain & Arthritis Centre, Udaipur, Rajasthan, India, 12Inserm DR Paris 5, Paris, France, 13ASST Spedali Civili-University of Brescia, Gussago, Brescia, Italy, 14Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey, 15Department of Rheumatology, Oslo University Hospital, Oslo, Norway, 16Aarhus University Hospital, Aarhus, Denmark, 17Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden, 18V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 19Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, 20Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece, 21National and Kapodistrian University of Athens, Athens, Greece

    Background/Purpose: Cardiovascular disease (CVD) in antiphospholipid syndrome (APS) is driven by antiphospholipid antibody-mediated immunothrombotic mechanisms and traditional cardiovascular risk factors (CVRFs). Although the EULAR recommendations…
  • Abstract Number: 0786 • ACR Convergence 2025

    A Machine Learning Approach to Understand Age as a Risk Factor for Complications After Total Hip Arthroplasty

    Chloe Heiting1, Yiyuan Wu2, Susan Goodman3, Peter Sculco4, Fei Wang2, Rich Caruana5, Peter Cram6, Said Ibrahim7 and Bella Mehta8, 1Northwell Health, New Hyde Park, NY, 2Weill Cornell Medicine, New York, NY, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 4Hospital for Special Surgery, New York, NY, 5Microsoft, Redmond, WA, 6University of Maryland School of Medicine, Baltimore, MD, 7Thomas Jefferson University, Philadelphia, PA, 8Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ

    Background/Purpose: Utilization of total hip arthroplasty (THA) has grown rapidly in the United States and worldwide. Postoperative complications and patient risk is of great consideration…
  • Abstract Number: 1109 • ACR Convergence 2025

    Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study

    Laurianne Simard1, Nathalie Amiable2, Ines Colmegna3, Anne-Sophie Julien4, Sonia Léger-Thériault5, Alexandra Godbout4, Lison Fournier6, Giuliana Alfonso5, Josiane Bourre-Tessier7, Marie Hudson8, Nicolas Richard9, Jean-Paul Makhzoum10, Arielle Mendel11, Sasha Bernatsky12, Marc Dionne6, Michael Libman5, Gaston De Serres6 and Paul Fortin13, 1Universite Laval, Quebec, QC, Canada, 2Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, 3The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 4Centre de recherche du CHU de Québec – Université Laval, Quebec, QC, Canada, 5MUHC, Montreal, Canada, 6Centre de recherche du CHU de Québec – Université Laval, Quebec, Canada, 7Centre hospitalier de l'Universite de Montreal, Montreal, QC, Canada, 8McGill University, Montréal, QC, Canada, 9Hopital Maisonneuve Rosemont, Montreal, QC, Canada, 10Universite de Montreal, Montreal, Canada, 11McGill University Health Centre, Montréal, QC, Canada, 12Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 13Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada

    Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARD) treated with B-cell-depleting therapies such as rituximab (RTX) have impaired humoral immune responses, increasing their susceptibility to…
  • Abstract Number: 1681 • ACR Convergence 2025

    Lymphoma and Other Malignancies in Sjögren’s Disease: Incidence, Predictive Factors, and Mortality Outcomes.

    Olga Rusinovich1, Zulema Plaza2, Monica Fernandez Castro3, Jose Rosas Gómez de Salazar4, Victor Martinez-Taboada5, Alex Olive6, Belén Serrano-Benavente7, Judit Font-Urgelles8, Angel Garcia-Aparicio9, Sara Manrique-Arija10, Jesús Alberto Garcia Vadillo11, Ruth Lopez-Gonzalez12, Javier Narváez13, Maria Beatriz Rodriguez14, Carlos Galisteo15, Jorge Juan Gonzalez Martin16, Paloma Vela Casasempere17, Rabadán Elena18, Antonio Naranjo19, Beatriz Paredes-Romero20, Leyre Riancho-Zarrabeitia21, Sheila Melchor Diaz22, Irene Altabás-González23, Sergi Heredia Martin24, Clara Moriano25, Mª Angeles Blazquez Cañamero26, Paula Estrada-Alarcón27, Enrique Judez28, Nerea Alcorta Lorenzo29, Javier Loricera30, Rosalía Martínez Pérez31, Fernando Sánchez-Alonso32 and Jose Luis Andreu33, 1Puerta de Hierro University Hospital, Boadilla del Monte, Spain, 2Research Unit, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain, 3PUERTA DE HIERRO HOSPITAL, Madrid, Spain, 4Hospital Marina Baixa, PALMA DE MALLORCA, Spain, 5Facultad de Medicina. Universidad de Cantabria, Santander, Spain, 6Solo practice, Barcelona, Spain, 7Hospital Gregorio Marañon, Madrid, Spain, 8Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 9Hospital Universitario de Toledo, Toledo, Spain, 10Hospital Regional Universitario Málaga, Malaga, Spain, 11Hospital Universitario La Princesa, Madrid, Spain, 12Zamora Health Complex, Salamanca, Spain, 13Hospital Universitario de Bellvitge, Barcelona, Spain, 14Canarias University Hospital, La Laguna- Tenerife, Spain, 15Hospital Parc Taulí, Sabadel, Sabadel, Spain, 16HM Sanchinarro Univeristary Hospital, Madrid, Spain, 17Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, 18Hospital Universitario Príncipe de Asturias, Alcala de Henares, Spain, 19Hospital Dr Negrin, PALMAS DE GRAN CANARIA (LAS), Spain, 20Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, 21Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, 2212 de Octubre University Hospital, Madrid, Spain, 23Complejo Hospitalario de Vigo, Vigo, Spain, 24Complex Hospitalari Moisès Broggi, Barcelona, Spain, 25Hospital León, LEON, Castilla y Leon, Spain, 26Hospital Ramon y Cajal, Madrid, Spain, 27Complex Universitari Hospital Moisès Broggi, Barcelona, Spain, 28Albacete University Hospital, Albacete, Spain, 29University Hospital Donostia, san sebastian, Spain, 30Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 31Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, 32Sociedad Española de Reumatología, Madrid, Spain, 33Hospital Universitario Puerta de Hierro, Majadahonda, Spain

    Background/Purpose: The association between Sjögren’s disease (SjD) and non-Hodgkin lymphoma (NHL) is well established, although reported standardized incidence ratios (SIRs) vary considerably across studies. In…
  • Abstract Number: 2323 • ACR Convergence 2025

    Short-term predictive factors for the development of psoriatic arthritis in patients with psoriasis: findings from a joint consultation between Rheumatology and Dermatology

    Mitndbaim Parra1, Marta Flores2, María Ángeles Puche-Larrubia3, Alejandro Escudero Contreras4, María Dolores López-Montilla5 and Clementina López Medina6, 11. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Cordoba, Spain, 21. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Spain, Spain, 3Reina Sofia University Hospital, Granada, Spain, 4IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 5Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, 6Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain

    Background/Purpose: Psoriatic Arthritis (PsA) is a chronic rheumatic disease that develops in up to one-third of patients with psoriasis. Identifying predictive factors for PsA in…
  • Abstract Number: 0142 • ACR Convergence 2025

    Risk Factors for Antiphospholipid Syndrome-associated Nephropathy: A Retrospective Cohort Analysis

    Xiaohan Wei1, Zhixia Yang2, Haoyu Pan2, Yuying Fan2, Jinyi Qian2, Shuyi Yu2 and Hui Shi3, 1Shanghai JiaoTong University, Shanghai, China (People's Republic), 2Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), 3Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)

    Background/Purpose: To identify independent clinical and laboratory risk factors associated with antiphospholipid syndrome-associated nephropathy (APSN) and highlight the clinical importance of early screening in high-risk…
  • Abstract Number: 0831 • ACR Convergence 2025

    Altered expression of CD11c and HLA-DR on monocyte subsets in individuals at risk of rheumatoid and psoriatic arthritis

    Klára Prajzlerová1, Olga Kryštůfková2, Hana Hulejová1, Nora Růžičková2, Petra Hánová1, Jiri Vencovsky3, Ladislav Šenolt2, Jiří Štolfa2 and Mária Filková2, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 3Institute of Rheumatology, Praha 8, Czech Republic

    Background/Purpose: Preclinical phases of rheumatoid arthritis (RA), including therapeutic interventions, have been extensively studied. There is a growing focus on individuals at risk for psoriatic…
  • Abstract Number: 1137 • ACR Convergence 2025

    Increased Risk of Cardiovascular Events and Mortality Related to Diffuse Idiopathic Skeletal Hyperostosis (DISH): A Systematic Review and Meta-Analysis

    Pitchaporn Yingchoncharoen1, Nattanicha Chaisrimaneepan2, Miriam Paz3, Chanokporn Puchongmart1, Ben thiravetyan1, Panat Yanpiset1 and Jerapas Thongpiya4, 1Texas Tech Health Sciences Center, Lubbock, TX, 2Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, 3Texas Tech University Health Sciences Center, Lubbock, 4Texas Tech University Health Sciences Center at Lubbock Program, Lubbock, TX

    Background/Purpose: Diffuse Idiopathic Skeletal Hyperostosis (DISH) is characterized by ossification and calcification of the entheses with prevalence increasing with age. It has been reported to…
  • Abstract Number: 1700 • ACR Convergence 2025

    Altered Gene Expression In Male SLE Is Mapped To a Male-Specific Y Chromosome Locus Associated with Microdeletions

    Mikhail Olferiev1, Kyriakos Kirou1, Emily Wu2, Dina Greenman1 and Mary Crow3, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Union City, NJ, 3Hospital for Special Surgery, New York

    Background/Purpose: SLE occurs more frequently in females than males, with relative prevalence 9-10:1. While the impact of hormones on immune function may contribute to the…
  • Abstract Number: 2378 • ACR Convergence 2025

    Factors Associated With Fatigue In Systemic Lupus Erythematosus: Data From The Almenara Lupus Cohort

    Alvaro Oyarce-Calderón1, Rocío Gamboa-Cárdenas2, Victor Pimentel-Quiroz3, Samira Garcia-Hirsh4, Zoila Rodríguez-Bellido5, Cesar Pastor-Asurza6, Risto Perich-Campos7, Graciela Alarcón8 and Manuel Ugarte-Gil9, 1Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, 2Universidad Científica del Sur, Lima, Peru, 3Universidad Científica del Sur, San Isidro, Peru, 4Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, 5Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, 6Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, 7Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, 8The University of Alabama at Birmingham, Oakland, CA, 9Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by a wide spectrum of clinical manifestations, fatigue being one of them; it is…
  • Abstract Number: 0148 • ACR Convergence 2025

    Air Pollution as a Trigger for Flares in Chronic Inflammatory Rheumatic Diseases: a Prospective Single-Center Study in the South of France

    Coralie Cruzel1, antonio Iannelli2, Alexandre Armengaud3, Sonia Oppo3, Marie Charlotte Trojani4, Stephanie Ferrero4, Veronique Breuil4, Eric Fontas5, Christian Roux4 and Clément Viala4, 12. Department of Clinical Research, Cimiez Hospital, CHU Nice, Université Côte d'Azur, Nice, France, France, France, 23. Centre Hospitalier Universitaire de Nice-Digestive Surgery and Liver Transplantation Unit, Archet 2 Hospital, 06202 Nice, France., NIce, France, 31. University Cote d’Azur, Rheumatology department, CHU Nice, France, Marseille, France, 41. University Cote d’Azur, Rheumatology department, CHU Nice, France, NIce, France, 52. Department of Clinical Research, Cimiez Hospital, CHU Nice, Université Côte d'Azur, Nice, France, NIce, France

    Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA), are chronic inflammatory rheumatic diseases. Despite significant advancements in their management through novel therapies, some patients continue to…
  • Abstract Number: 0833 • ACR Convergence 2025

    Sputum Anti-CCP-IgA and NET-Associated Proteins Predict Risk and Timing of the Transition From Systemic Autoimmunity to Classified RA

    Timothy Wilson1, Claudia Lugo2, Marie Feser3, Mark Gillespie4, Troy Torgerson5, Gary Firestein6, V. Michael Holers7, Kevin Deane8 and Kristen Demoruelle9, 1Thomas Jefferson University, Philadelphia, PA, 2University of Colorado, Denver, CO, 3University of Colorado Anschutz Medical Campus, Aurora, CO, 4Allen Institute for Immunology, Seattle, WA, 5Allen Institute for Immunology, Enumclaw, WA, 6University of California, San Diego, San Diego, CA, 7University of Colorado Anschutz Medical Campus, Aurora, 8University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 9University of Colorado Anschutz Medical Campus, Golden, CO

    Background/Purpose: The presence of serum anti-CCP-IgG antibodies can predict the future development of clinically evident RA. Neutrophil extracellular trap (NET) formation can be a source…
  • Abstract Number: 1148 • ACR Convergence 2025

    Interstitial Lung Disease in MCTD: A Retrospective Cohort Study at a Large Tertiary Medical Center

    Alana Haussmann1 and Elizabeth Volkmann2, 1University of California Los Angeles, Los Angeles, CA, 2Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA

    Background/Purpose: Mixed connective tissue disease (MCTD) is a rare autoimmune condition defined by the presence of anti-U1-ribonucleoprotein (RNP) antibodies and clinical features of at least…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology